RT Journal Article
SR Electronic
T1 A prospective cohort study of prodromal Alzheimer’s disease: Prospective Imaging Study of Ageing: Genes, Brain and Behaviour (PISA)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.04.20091140
DO 10.1101/2020.05.04.20091140
A1 Michelle K Lupton
A1 Gail A Robinson
A1 Robert J Adam
A1 Stephen Rose
A1 Gerard J Byrne
A1 Olivier Salvado
A1 Nancy A Pachana
A1 Osvaldo P Almeida
A1 Kerrie McAloney
A1 Scott D Gordon
A1 Parnesh Raniga
A1 Amir Fazlollahi
A1 Ying Xia
A1 Amelia Ceslis
A1 Saurabh Sonkusare
A1 Qing Zhang
A1 Mahnoosh Kholghi
A1 Mohan Karunanithi
A1 Philip E Mosley
A1 Jinglei Lv
A1 Jessica Adsett
A1 Natalie Garden
A1 Jurgen Fripp
A1 Nicholas G Martin
A1 Christine C Guo
A1 Michael Breakspear
YR 2020
UL http://medrxiv.org/content/early/2020/06/16/2020.05.04.20091140.abstract
AB This prospective cohort study, “Prospective Imaging Study of Ageing: Genes, Brain and Behaviour” (PISA) seeks to characterise the phenotype and natural history of healthy adult Australians at high future risk of Alzheimer’s disease (AD). In particular, we are recruiting mid-life Australians with high and low genetic risk of dementia to discover biological markers of early neuropathology, identify modifiable risk factors, and establish the very earliest phenotypic and neuronal signs of disease onset. PISA utilises genetic prediction to recruit and enrich a prospective cohort and follow them longitudinally. Online surveys and cognitive testing are used to characterise an Australia-wide sample currently totalling nearly 3,000 participants. Participants from a defined at-risk cohort and positive controls (clinical cohort of patients with mild cognitive impairment or early AD) are invited for onsite visits for lifestyle monitoring, detailed neurocognitive testing, blood sample donation, plus functional, structural and molecular neuroimaging. This paper describes recruitment of the PISA cohort, study methodology and baseline demographics.Author Approval All authors have seen and approved this manuscript.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPISA is funded by a National Health and Medical Research Council (NHMRC) Boosting Dementia Research Initiative - Team Grant [APP1095227], to MB, NM, GB, SR, CCG, OS, OA, GAR, NP. MKL is supported by a Boosting Dementia Leadership Fellowship [APP1140441]. GAR is supported by a Boosting Dementia Research Leadership Fellowship [APP1135769].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Research Ethics Committees (HREC) of QIMR Berghofer Medical Research Institute and the University of QueenslandAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFollowing completion of each wave (baseline, follow-up) and appropriate quality control, de-identified PISA data will be made available to other research groups upon appropriate request and evidence on institutional ethics approval for local data storage, analysis and security.